Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 105

Report ID: 2094

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
In 2018, the global Hemophilia A and B Recombinant Factor Replacement Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Hemophilia A and B Recombinant Factor Replacement Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemophilia A and B Recombinant Factor Replacement Therapy development in United States, Europe and China.

The key players covered in this study
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure

Market segment by Type, the product can be split into
Haemophilia A
Haemophilia B

Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers 

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Hemophilia A and B Recombinant Factor Replacement Therapy status, future forecast, growth opportunity, key market and key players.
To present the Hemophilia A and B Recombinant Factor Replacement Therapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Hemophilia A and B Recombinant Factor Replacement Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth Rate by Type (2014-2025)
1.4.2 Haemophilia A
1.4.3 Haemophilia B
1.5 Market by Application
1.5.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers 
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Size
2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Growth Trends by Regions
2.2.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions (2014-2025)
2.2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Manufacturers
3.1.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Manufacturers (2014-2019)
3.1.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Ratio (CR5 and HHI)
3.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players Head office and Area Served
3.3 Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product/Solution/Service
3.4 Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2014-2019)
4.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2014-2019)

5 United States
5.1 United States Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
5.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in United States
5.3 United States Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
5.4 United States Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

6 Europe
6.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
6.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Europe
6.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
6.4 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

7 China
7.1 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
7.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in China
7.3 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
7.4 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

8 Japan
8.1 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
8.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Japan
8.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
8.4 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
9.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Southeast Asia
9.3 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
9.4 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

10 India
10.1 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
10.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in India
10.3 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
10.4 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

11 Central & South America
11.1 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2014-2019)
11.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Central & South America
11.3 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
11.4 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application

12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.1.4 Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.1.5 Pfizer Recent Development
12.2 Novo Nordisk
12.2.1 Novo Nordisk Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.2.4 Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.2.5 Novo Nordisk Recent Development
12.3 Baxalta
12.3.1 Baxalta Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.3.4 Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.3.5 Baxalta Recent Development
12.4 Bayer
12.4.1 Bayer Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.4.4 Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.4.5 Bayer Recent Development
12.5 Biogen
12.5.1 Biogen Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.5.4 Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.5.5 Biogen Recent Development
12.6 CSL Behring
12.6.1 CSL Behring Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.6.4 CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.6.5 CSL Behring Recent Development
12.7 Emergent Biosolutions
12.7.1 Emergent Biosolutions Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.7.4 Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.7.5 Emergent Biosolutions Recent Development
12.8 Spark therapeutics
12.8.1 Spark therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.8.4 Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.8.5 Spark therapeutics Recent Development
12.9 Uniqure
12.9.1 Uniqure Company Details
12.9.2 Company Description and Business Overview
12.9.3 Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
12.9.4 Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2014-2019)
12.9.5 Uniqure Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details